Resmetirom in Nonalcoholic Fatty Liver Disease

What is the Purpose of this Study?

The purpose of this study is to determine the safety and effectiveness of an investigational drug called resmetirom in people with NASH/NAFLD and compensated cirrhosis. Specifically, the study will examine how well resmetirom works for the reduction of LDL-cholesterol, triglycerides, and other elevated lipids, as well as for reduction in liver fat. Researchers also want to learn the effectiveness of resmetirom in reducing blood and imaging markers of NASH/NAFLD. Study procedures include blood draws, electrocardiograms, and imaging, among others. Resmetirom works together with a type of thyroid hormone receptor in the liver to decrease the amount of fat that has built up in the liver and possibly reduce the inflammation and fibrosis that are associated with NASH.


Eligibility

  • * For patients who completed MAESTRO-NAFLD-1, completed the Week 52 visit, and completed the Week 56 visit within 90 days of the Extension Day 1 visit, and are willing to participate in MAESTRO-NAFLD-OLE and provide written informed consent.
  • * For patients who screen failed MAESTRO-NASH, must provide written informed consent for MAESTRO-NAFLD-OLE and must have screened and met all eligibility requirements for MAESTRO-NASH within 90 days of the Extension Day 1 visit for MAESTRO-NAFLD-OLE and have a liver biopsy that is ineligible for MAESTRO-NASH within 6 months of the Extension Day 1 visit. Eligible liver biopsy for MAESTRO-NAFLD-OLE must have one of the following results:
  • * NAS = 3, steatosis 1, ballooning 1, inflammation 1, OR NAS = 3, ballooning 0, with F1B, F2 or F3
Show more

Where can I participate?

Beverly

More about this Clinical Trial

What is the full name of this clinical trial?

A 52-Week, Phase 3 Open-Label Extension Study, with a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom in Patients with Non-alcoholic Fatty Liver Disease , MAESTRO-NAFLD-Open-Label-Extension

Study Details
Disease Type/Condition

Nonalcoholic Fatty Liver Disease (NAFLD)

Principal Investigator

Ayoub, Walid

Co-Investigators

Elvira Rodriguez, Hirsh Trivedi

Age Group

Adult

Phase

III

IRB Number

STUDY00002518

ClinicalTrials.gov ID

NCT04951219

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Nonalcoholic Fatty Liver Disease (NAFLD)

Principal Investigator

Ayoub, Walid

Age Group

Adult

Phase

III

IRB Number

MGL-3196-18

ClinicalTrials.gov ID

NCT04951219

Key Eligibility
ClinicalTrials.gov

Contact
Email
clinicaltrials@cshs.org